FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity.
about
Macrocyclic histone deacetylase inhibitorsImproved total synthesis of the potent HDAC inhibitor FK228 (FR-901228)Metalloprotein–Inhibitor Binding: Human Carbonic Anhydrase II as a Model for Probing Metal–Ligand Interactions in a Metalloprotein Active SiteThe Pharmacological Potential of Non-ribosomal Peptides from Marine Sponge and TunicatesHistone deacetylase 3 (HDAC 3) as emerging drug target in NF-κB-mediated inflammationHistone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.Natural products as sources of new drugs over the 30 years from 1981 to 2010Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1).Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphomaPhase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304).Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.Histones and their modifications in ovarian cancer - drivers of disease and therapeutic targets.Synthesis and conformation-activity relationships of the peptide isosteres of FK228 and largazole.Identification and characterization of the spiruchostatin biosynthetic gene cluster enable yield improvement by overexpressing a transcriptional activator.Total Synthesis and Biological Studies of TMC-205 and Analogues as Anticancer Agents and Activators of SV40 Promoter.Peripheral T-cell lymphoma: review and updates of current management strategiesPhase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)Romidepsin: evidence for its potential use to manage previously treated cutaneous T cell lymphoma.Total synthesis and biological mode of action of largazole: a potent class I histone deacetylase inhibitor.Interpreting clinical assays for histone deacetylase inhibitors.Histone deacetylase inhibitors with enhanced enzymatic inhibition effects and potent in vitro and in vivo antitumor activities.Augmenting antitumor immune responses with epigenetic modifying agents.Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphomaHistone deacetylase inhibitors in clinical studies as templates for new anticancer agents.Thailandepsins: bacterial products with potent histone deacetylase inhibitory activities and broad-spectrum antiproliferative activities.Romidepsin in the treatment of cutaneous T-cell lymphoma.Characterization of a gene cluster responsible for the biosynthesis of anticancer agent FK228 in Chromobacterium violaceum No. 968FK228 Analogues Induce Fetal Hemoglobin in Human Erythroid Progenitors.Chromopeptide A, a highly cytotoxic depsipeptide from the marine sediment-derived bacterium Chromobacterium sp. HS-13-94.HIF-1α pathway: role, regulation and intervention for cancer therapy.Romidepsin targets multiple survival signaling pathways in malignant T cellsDetermination of the cyclic depsipeptide FK228 in human and mouse plasma by liquid chromatography with mass-spectrometric detection.P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228Low Dose Histone Deacetylase Inhibitor, Depsipeptide (FR901228), Promotes Adenoviral Transduction in Human Rhabdomyosarcoma Cell LinesMAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor.Epigenetic mechanisms in cerebral ischemia.Synthesis and histone deacetylase inhibitory activity of largazole analogs: alteration of the zinc-binding domain and macrocyclic scaffoldDiscovery and mechanism of natural products as modulators of histone acetylation.Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphomaEpigenetic changes in gliomas.
P2860
Q24629065-6E587B12-3DDA-4653-BB3D-DE8B91052747Q24633204-E37569EF-F0D9-476B-A186-D789C6CF153AQ27678293-245AEE58-BE85-4A4E-BE62-8D5C5607C42FQ28074153-13C1A173-10E7-4E91-BCBC-9FF64FC3F8A4Q28076052-0432826B-465E-4A23-BF58-4A6EAA464A01Q28537694-BBD55A56-5837-4475-9B4D-D75BCE2B4703Q29616640-4E470DB4-2ADD-4A21-AEA3-FE402180C661Q33235403-0BCCC94A-D0CE-4AFE-BCF7-A870861E18D8Q33386623-CBC03AD7-7015-4E81-838C-860168A83E81Q33392042-E6E28663-30FD-4B88-AE1D-7BBE6A001E6CQ33394324-3C4BEF79-F911-424D-B8DE-DB10CCEF5419Q33741828-B16AA0CA-D0C5-4EC5-8BB7-8251CAEF92A9Q33893992-12B156E5-ED99-4760-BD71-5C804B19F45CQ34051299-7E5FC513-D245-4D30-BFE1-1CBE339DD685Q34063696-83B64F93-31CF-4519-B465-7C05CAC2BACCQ34479082-504D7DC1-EC2E-4625-B827-01716F5AADA1Q34510205-5F4FB638-1AEB-4B06-BAFE-EC92CA189102Q34729026-6EBCC021-1BF2-4743-ACB7-61378B417D16Q34958178-A9344584-BA51-4E60-A8BE-507D1C50CB20Q35003657-5217FEAC-FBF4-4F3A-BC73-D84E17FFD62AQ35042270-9A72734A-104E-4011-9F9E-F93BF1CE4F3FQ35048054-7E9AE329-24CF-4965-B3F4-4EDE28DB95E0Q35186682-A0611691-B9EC-4E58-84BD-8480C27F1DFFQ35214924-86F6F99D-3F83-4B92-B777-EE8A2421372BQ35476003-86547116-87CD-4AAD-A6D1-FED0019E2AC6Q35683831-C2FA1154-6919-4409-BF80-EC11122C62AEQ35913058-1C6C5D67-A072-4A08-8B93-1E4358A30D20Q35986327-D262C585-7C73-494B-B4DE-EDB6170F0BCFQ36237655-358786BD-9FE8-4318-BD35-BC08D31A4A3CQ36238647-AC0185FD-7F15-4F19-B80D-5F19D5D03ECCQ36254237-69F61028-D87A-4279-98B4-F419F90013A5Q36571570-CBD73B7F-30AE-438E-958F-34A6026C4D26Q36621938-A017E1A0-2E46-4D35-86F9-4E278A77B950Q36674393-90A182C1-1428-4853-B531-0021CBB32FF6Q36850845-4BF005D1-D69F-4C95-905D-0A3D1D447201Q37150340-5E28AC30-00BD-4FA8-8B1E-7A1F4EEDB54EQ37170927-7AA4980E-B249-456A-AE5B-E9DD47D919D5Q37242496-775B7169-577C-4EC4-A806-7E58BBD7759BQ37253554-8F47B99E-3AE5-41A1-8F40-3ECFCCD2B8F0Q37287032-5DC40658-EDCC-4565-B0A4-5DC02763152E
P2860
FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity.
description
1994 nî lūn-bûn
@nan
1994 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի մարտին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
FR901228, a novel antitumor bi ...... rties, and antitumor activity.
@ast
FR901228, a novel antitumor bi ...... rties, and antitumor activity.
@en
FR901228, a novel antitumor bi ...... rties, and antitumor activity.
@nl
type
label
FR901228, a novel antitumor bi ...... rties, and antitumor activity.
@ast
FR901228, a novel antitumor bi ...... rties, and antitumor activity.
@en
FR901228, a novel antitumor bi ...... rties, and antitumor activity.
@nl
prefLabel
FR901228, a novel antitumor bi ...... rties, and antitumor activity.
@ast
FR901228, a novel antitumor bi ...... rties, and antitumor activity.
@en
FR901228, a novel antitumor bi ...... rties, and antitumor activity.
@nl
P2093
P1476
FR901228, a novel antitumor bi ...... rties, and antitumor activity.
@en
P2093
Nakajima H
Nishimura M
P304
P577
1994-03-01T00:00:00Z